Cordes M, Hosten N, Gräf K J, Wenzel K W, Venz S, Keske U, Eichstädt H, Felix R
Strahlenklinik und Poliklinik, Universitätsklinikum Rudolf Virchow, Freie Universität Berlin.
Rofo. 1994 Jan;160(1):11-5. doi: 10.1055/s-2008-1032365.
Recently, [111In]-DTPA-D-phenylalanine-octreotide was introduced for clinical use. This radioligand binds specifically to somatostatin receptors and is suitable for SPECT examinations. The aim of this study was to clarify whether an increased somatostatin receptor density can be imaged and quantified in patients with endocrine ophthalmopathy (e.o.). 7 patients between 34 and 55 years with e.o. at stages III to VI and 4 controls between 38 and 63 years were examined. All patients and controls received approximately 200 MBq [111In]-DTPA-D-phenylalanine-octreotide by IV injection. A SPECT examination was performed 4 hours after injection and a normalised tracer uptake (A(n)) was calculated for both orbitae. In patients with e.o. the values of A(n) were significantly higher compared with controls (P = 0.002). There was a correlation between A(n) and exophthalmus stages according to Hertel with r = 0.844 (P = 0.001). These results indicate that [111In]-DTPA-D-phenylalanine-octreotide SPECT might be useful for the in vivo assessment of an increased somatostatin receptor density in e.o. These findings could have an impact on the treatment with somatostatin analogous in e.o.
最近，[111In]-二乙三胺五乙酸-D-苯丙氨酸-奥曲肽被引入临床应用。这种放射性配体特异性结合生长抑素受体，适用于单光子发射计算机断层扫描（SPECT）检查。本研究的目的是阐明在内分泌性眼病（e.o.）患者中，增加的生长抑素受体密度是否可以成像和定量。对7例年龄在34至55岁之间、处于III至VI期的e.o.患者和4例年龄在38至63岁之间的对照者进行了检查。所有患者和对照者均通过静脉注射接受了约200兆贝可的[111In]-二乙三胺五乙酸-D-苯丙氨酸-奥曲肽。注射后4小时进行SPECT检查，并计算双侧眼眶的标准化示踪剂摄取量（A(n)）。e.o.患者的A(n)值与对照者相比显著更高（P = 0.002）。根据赫特尔法，A(n)与眼球突出度分期之间存在相关性，r = 0.844（P = 0.001）。这些结果表明，[111In]-二乙三胺五乙酸-D-苯丙氨酸-奥曲肽SPECT可能有助于在体内评估e.o.中生长抑素受体密度的增加。这些发现可能会对e.o.中生长抑素类似物的治疗产生影响。
